Evidence map›Paper›PMID 28838186›Full record

ArticleThe Journal of infectious diseases2017

Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April-November 2015.

Lynda U Osadebe, Adam MacNeil, Hashim Elmousaad, Lora Davis, Jibrin M Idris, Suleiman A Haladu, Olorunsogo B Adeoye, Patrick Nguku, Uneratu Aliu-Mamudu, Elizabeth Hassan and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Lynda U OsadebeGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Adam MacNeilGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Hashim ElmousaadGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Lora DavisGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Jibrin M IdrisNigerian Stop the Transmission of Polio Program, AbujaNigeria.
Suleiman A HaladuNigerian Stop the Transmission of Polio Program, AbujaNigeria.
Olorunsogo B AdeoyeNigerian Stop the Transmission of Polio Program, AbujaNigeria.
Patrick NgukuNigeria Field Epidemiology and Laboratory Training Programs.
Uneratu Aliu-MamuduNational Primary Health Care Development Agency.
Elizabeth HassanNational Primary Health Care Development Agency.
John VertefeuilleGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Peter BlolandGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta Georgia.
Centers for Disease Control and Prevention · USNational Primary Health Care Development Agency · NGAfrican Field Epidemiology Network · NG

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Background: Kano State, Nigeria, introduced inactivated polio vaccine (IPV) into its routine immunization (RI) schedule in March 2015 and was the pilot site for an RI data module for the National Health Management Information System (NHMIS). We determined factors impacting IPV introduction and the value of the RI module on monitoring new vaccine introduction. Methods: Two assessment approaches were used: (1) analysis of IPV vaccinations reported in NHMIS, and (2) survey of 20 local government areas (LGAs) and 60 associated health facilities (HF). Results: By April 2015, 66% of LGAs had at least 20% of HFs administering IPV, by June all LGAs had HFs administering IPV and by July, 91% of the HFs in Kano reported administering IPV. Among surveyed staff, most rated training and implementation as successful. Among HFs, 97% had updated RI reporting tools, although only 50% had updated microplans. Challenges among HFs included: IPV shortages (20%), hesitancy to administer 2 injectable vaccines (28%), lack of knowledge on multi-dose vial policy (30%) and age of IPV administration (8%). Conclusion: The introduction of IPV was largely successful in Kano and the RI module was effective in monitoring progress, although certain gaps were noted, which should be used to inform plans for future vaccine introductions.

Indexed as

Immunization ProgramsDisease EradicationHumansImmunization ScheduleNigeriaPoliomyelitisPoliovirus Vaccine, InactivatedPoliovirus Vaccine, Inactivatedimmunization information systemsInactivated polio vaccineroutine immunizationvaccination introduction

Identifiers

PMID28838186
PMCPMC5844228
OpenAlexW2735345087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.